Arrowhead Pharmaceuticals (ARWR) is advancing with the FDA approval of its drug REDEMPLO, marking a key step in its commercialization efforts. The company’s cardiometabolic pipeline, including updates to REDEMPLO and the dual-target RNAi drug ARO-DIMER-PA, supports future growth potential. Additionally, ARWR’s CNS drug ARO-MAPT, targeting tauopathies related to Alzheimer's, is expected to release Phase 1 data in the second half of 2026, which could boost the company’s valuation. Despite some challenges in commercialization, Arrowhead’s strong $1.8 billion balance sheet, strategic partnerships, and leadership inspire investor confidence in its growth prospects.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
